Literature DB >> 27497639

Identification of UQCRB as an oxymatrine recognizing protein using a T7 phage display screen.

Yan-Hui Sun1, Xiao-Yuan Zhang2, Wei-Qun Xie3, Guang-Jian Liu4, Xi-Xin He5, Ya-Li Huang6, Guang-Xian Zhang7, Jian Wang8, Zao-Yuan Kuang9, Ren Zhang10.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Sophora flavescens Aiton (Radix Sophorae Flavescentis, Kushen) is used in traditional Chinese medicine to treat chronic hepatitis B (CHB), and has the ability to clear heat and dampness from the body. Oxymatrine is one of the major bioactive compounds extracted from Sophora flavescens Aiton and constitutes more than 90% of the oxymatrine injection commonly used for CHB treatment in clinics in China. AIM OF THE STUDY: We aim to analyze the protein binding target of oxymatrine in treating CHB by screening a T7 phage display cDNA library of human CHB and examine the biochemistry of protein-ligand binding between oxymatrine and its ligands.
MATERIALS AND METHODS: A T7 phage cDNA library of human CHB was biopanned by affinity selection using oxymatrine as bait. The interaction of oxymatrine with its candidate binding protein was investigated by affinity assay, molecular docking, Isothermal Titration Calorimetry (ITC) and Surface Plasmon Resonance (SPR).
RESULTS: A library of potential oxymatrine binding peptides was generated. Ubiquinol-cytochrome c reductase binding protein (UQCRB) was one of the candidate binding proteins of oxymatrine. UQCRB-displaying T7 phage binding numbers in the oxymatrine group were significantly higher than that in the control group, biotin group, and matrine group (p<0.05 or p<0.01). Three-dimensional structure modeling of the UQCRB with oxymatrine showed that their binding interfaces matched and oxymatrine inserted into a deeper pocket of UQCRB, which mainly involved amino acid residues Tyr21, Arg33, Tyr83, Glu84, Asp86, Pro88, and Glu91. The binding affinity constant (Kb) from SPR was 4.2mM. The Kb from ITC experiment was 3.9mM and stoichiometry was fixed as 1, which fit very well with the result of SPR. The binding of oxymatrine to UQCRB was driven by strong enthalpy forces such as hydrogen bonds and polar interactions as the heat released was about 157kcal/mol and ΔG was less than zero.
CONCLUSIONS: In this study, using the T7 phage display system, we have identified UQCRB as a direct binding protein of oxymatrine. Furthermore, the specificity and molecular interaction of oxymatrine with UQCRB were also determined. The binding of UQCRB to oxymatrine suggests that UQCRB is a potential target of oxymatrine in treating CHB. These results provide new understanding into the mechanism of oxymatrine and insights into the strategy on the treatment of CHB.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Chronic hepatitis B; ITC; Oxymatrine; Oxymatrine (PubChem CID: 114850); SPR; UQCRB

Mesh:

Substances:

Year:  2016        PMID: 27497639     DOI: 10.1016/j.jep.2016.08.007

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  5 in total

Review 1.  Virus-Derived Peptides for Clinical Applications.

Authors:  Mingying Yang; Kegan Sunderland; Chuanbin Mao
Journal:  Chem Rev       Date:  2017-07-19       Impact factor: 60.622

2.  Kushenin combined with adefovir dipivoxil affects the HBV-DNA load in serum, immune functions and liver functions of patients with chronic hepatitis B.

Authors:  Jing Feng; Jiandong Huang; Zhiqin Li
Journal:  Exp Ther Med       Date:  2017-10-06       Impact factor: 2.447

3.  A network pharmacology approach to determine the synergetic mechanisms of herb couple for treating rheumatic arthritis.

Authors:  Xi-Xi Xu; Jian-Ping Bi; Li Ping; Ping Li; Fei Li
Journal:  Drug Des Devel Ther       Date:  2018-04-24       Impact factor: 4.162

4.  Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Jing-Hao Zhang; Xin Zhang; Zhen-Hua Zhou; Xiao-Jun Zhu; Chao Zheng; Man Li; Shu-Gen Jin; De-Wen Mao; Jing-Dong Xue; Wei-Bing Shi; Xiao-Ling Chi; Xian-Bo Wang; Xiao-Dong Li; Yong Li; Hui Wang; Qin Li; Da-Qiao Zhou; Cheng-Bao Wang; Chang-He Shi; Cheng-Zhong Li; Jian-Hua Wu; Xiao-Ni Kong; Xue-Hua Sun; Yue-Qiu Gao
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-25       Impact factor: 2.629

5.  Transgenic hepatitis B: a new model of HBV infection.

Authors:  Hubert D-J Daniel; Michael Torbenson
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.